Polyhexanide (PHMB) – properties and applications in medicine by Szkołuda, Patrycja & Karpiński, Tomasz M.
ISSN 2449-8955 
European Journal  
of Biological Research 
Review Article 
 
European Journal of Biological Research 2020; 10(3): 225-231 
DOI: http://dx.doi.org/10.5281/zenodo.3956819  
Polyhexanide (PHMB) – properties and applications            
in medicine 
Patrycja Szkołuda1, Tomasz M. Karpiński2*  
1 Student Scientific Club of Medical Microbiology, Chair and Department of Medical Microbiology, Poznań University      
of Medical Sciences, Wieniawskiego 3, 61-712, Poznań, Poland 
2 Chair and Department of Medical Microbiology, Poznań University of Medical Sciences, Wieniawskiego 3, 
61-712, Poznań, Poland 
*Correspondence: E-mail: patszkoluda@gmail.com; tkarpin@ump.edu.pl 
Received: 15 June 2020; Revised submission: 14 July 2020; Accepted: 22 July 2020 
 
http://www.journals.tmkarpinski.com/index.php/ejbr 
Copyright: © The Author(s) 2020. Licensee Joanna Bródka, Poland. This article is an open access article distributed under the 
terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/) 
ABSTRACT: Polyhexamethylene biguanide (PHMB) is one of the many antiseptics available in the 
medicine. It stands out from the others with its numerous advantages. It has a low toxicity factor, chemical 
stability, and bactericidal effect on most microorganisms. PHMB is used in many areas of medicine, 
veterinary medicine, gastronomy, and industry. The application of polyhexanide in the treatment of chronic 
wounds allows for fast regeneration and reduced time of wound treatment and hospitalization. According to 
the Recommendations of the Polish Wound Treatment Society, PHMB is recommended in treatment of 
critically colonized wounds, wounds at risk infection, burns, and decontamination of acute and chronic 
wounds, and as second choice in infected wounds. 
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1. INTRODUCTION 
Chronic wounds are very important medical problem. It is estimated that about 1-1.5% of the 
population suffers from chronic wounds. Simultaneously, this illness affected approx. 3% of the population 
above 60 years of age [1, 2]. It is supposed that in Poland there are almost 500,000 of such patients [2]. In 
Poland, according to the guidelines, the following antiseptics are used to treat wounds: octenidine 
dihydrochloride, polyhexanide, PVP-iodine and products based on hypochlorite [2, 3]. This article provides 
information on polyhexanide (PHMB). 
2. CHEMICAL ASPECTS 
Poly(hexamethylene)biguanide hydrochloride (PHMB) is one of the most effective surface-disinfectant 
and anti-infective agent. It is a biocide from the bisbiguanid family and characterized by excellent anti-
microbial activity. Moreover PHMB (Figure 1) is chemically stable and has a low toxicity index [4]. 
Research on PHMB from the 20th century has shown that poly-biguanides are strongly antibacterial, 
compared to molar particles carrying only one group of biguanide. In polyhexane the number of biguanide 
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residue is n = 2-40, and an optimal number of methylene groups in the walk between the biguanide residues is 
m = 6. The terminal groups of this chemical compound are amine and cyanoguanidine [5]. 
Most commonly used method for polyhexanidine synthesis is polycondensation of sodium 
dicyandiamide and hexamethylenediamine in two stages [4]. 
 
 
Figure 1. Chemical structure of PHMB. 
3. TOXICITY ASPECTS 
According to the Commission Regulations (EU) No. 944/2013 and 2019/831, the PHMB is classified 
as CMR 2 (Carcinogen of category 2). CMR substances are substances that are classified as carcinogenic, 
mutagenic, or toxic for reproduction in cosmetic products [6, 7]. In the opinion of the Scientific                  
Committee on Consumer Safety the use of PHMB as a preservative in all cosmetic products is safe up                    
to 0.1% [8]. 
Polyhexamethylene biguanide hydrochloride (PHMB HCl) was classified as a hepatic tumorigen in 
mice. In the studies was used the highest dose (30 mg of 10% PHMB HCl in ethanol), applied to the skin 
daily (5 days/week) for 80 weeks. An increase in the incidence of liver tumors was observed and statistically 
significant was only for liver tumors of endothelial origin. In this group was observed high mortality (76 to 
78% of animals died) [8, 9]. PHMB was also evaluated for use in product-type 1 (human hygiene), product-
type 5 (drinking water), and product-type 6 (preservatives for products during storage), and product-type 9 
(fibre, leather, rubber and polymerised materials preservatives), as defined in Annex V to Regulation (EU) No 
528/2012. PHMB is not approved as an active substance for use in biocidal products of product-types 1, 5, 6, 
and 9, since the risk identified in the human health and environmental assessments was regarded as 
unacceptable [10, 11].  
Among side effects, PHMB can lead to dermal and ocular irritation, dermal and oral toxicity [8]. 
Moreover, two cases of a possible anaphylactic reaction triggered by PHMB were described [12]. One patient 
with a grade III anaphylactic reaction had IgE against both PHMB and chlorhexidine [13]. 
The use of PHMG as a component of aerosol disinfectants and air humidifiers is widespread. However, 
a causal link has been proven between the use of such disinfectants and the development of diffuse pulmonary 
fibrosis and other idiopathic fibrous interstitial pneumonias. Mice that received intravenous guanidine PHMG 
(1 mg/kg = 0.001 ug/mg) showed pulmonary oedema, inflammatory cell leakage, increased lung water 
accumulation and decreased collagen content [14]. The most known and important contraindications for 
PHMB are: the above mentioned possible allergy and the application during the first 4 months of pregnancy 
(in later stages of pregnancy its use should follow strict observance of a benefit-risk assessment). Naturally, 
the peritoneal lavage with PHMB in septic peritonitis is also contradicted [15].  
4. MADE OF ACTION 
Scientists established that the killer effect of PHMB is to affect the cytoplasmic membrane of 
microorganisms and damage it immediately. They act through a dual mechanism of membrane integrity 
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disruption and selective condensation and chromosome damage. After being combined with negatively 
charged phosphate groups of phospholipids present on the bacterial cell membrane, leads to its stiffening and 
tearing. It subsequently leads to the death of the bacterial cell [4]. Diffusion and irreversible loss of potassium 
from the intracellular pool of K+ ions occurs [16]. Another unique feature recently identified for polyhexanide 
is its intracellular bactericidal activity, considered an important property in the potential treatment of skin 
infections caused by intracellular bacteria [17]. 
The results of research carried out on human osteoblasts (hFOB) and endothelial cells raise doubts 
about the positive results of the use of PHMB in bone cement in the management of total arthroplast 
infections. The data showed that even at very low concentrations polyhexanide has a negative effect on bone 
cell viability and number [18]. 
5. APPLICATION 
Polyhexanide-containing agents have been used in various areas, mainly for disinfection of solid 
surfaces in hospitals and veterinary clinics at 0.1-0.2% concentration. PHMB is applied in rinses, thanks to its 
effectiveness in inhibiting biofilm regrowth. The research has shown that oral rinses containing 0.04% and 
0.12% PHMB inhibit the growth of dental plaque and reduce the number of bacteria in the oral cavity much 
more effectively than placebo and triclosan, but much less than chlorhexidine [19]. 
Polyhexanide is increasingly used as an active ingredient in a number of products, such as wet wipes, 
wound winding solutions, sterile dressings and disinfectants, as well as in personal and pharmaceutical 
hygiene products to treat chronic wounds and burns [20]. Products containing polyhexanide are becoming 
increasingly important in the treatment of wounds worldwide. They are eagerly used by patients with pain-
sensitive wounds, without significantly changing their quality of life, but with a positive impact on their well-
being [21]. 
Polyhexanide is currently considered one of the most suitable antiseptics for chronic wounds, epithelial 
and endothelial lesions, including second degree burns. Apart from its antiseptic efficacy, it does not inhibit 
the reepithelialization process [22]. It also prevents secondary bacterial infection. All these advantages have 
contributed to a reduction in the number of dressings and thus in treatment costs [23]. A purified collagen 
matrix containing polyhexamethylene biguanide with antibacterial properties was developed to support 
wound healing. The dressing consists of two layers of type I collagen matrix and has the ability to quench 
proteolytic enzymes [24]. 
Polyhexanide-based antiseptics are an alternative procedure for the care of healthy exit sites and an 
effective and safe therapy to prevent exit site infection (ESI) and peritonitis, which are common peritoneal 
dialysis (PD) complications [25]. Agents containing 0.02% polyhexanide can be effectively used for 
perioperative antiseptic eye prophylaxis [26] and in antibacterial fluids for optical lens containers in order to 
prevent the formation of biofilm by myco-organisms [27]. In dentistry, PHMB in concentrations of 0.05-0.2% 
is added to root canal sealants (to zinc eugenol cement), thanks to its antibacterial properties. It is aimed at 
maintaining a sterile environment of the prepared root canals [28]. 
In Poland are used antiseptics containing PHMB + Ringer solution, PHMB + betaine and PHMB + 
poloxamer. According to the Recommendations of the Polish Wound Treatment Society, PHMB is 
recommended in treatment of critically colonized wounds, wounds at risk infection, burns, and 
decontamination of acute and chronic wounds, and as second choice in infected wounds [2]. 
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6. ANTIMICROBIAL ACTIVITY 
Polyhexanide is effective against yeasts, viruses, Gram-positive and Gram-negative bacteria and some 
parasites. The significance of PHMB as an antiseptic substance in the treatment of infected wounds and in 
decolonization of skin with bacteria in biofilms has increased. Many in vitro studies evaluated the 
effectiveness of antiseptics, including PVP-iodine, octenidine dihydrochloride (OCT), polyhexanide (PHMB), 
hydrogen peroxide, chlorhexidine digluconate (CHX) or ethacridine lactate in infections caused by 
Staphylococcus strains, Pseudomonas aeruginosa, Enterococcus faecalis and Klebsiella pneumoniae. Studies 
showed that octenidine and polyhexanidine were the most effective in relation to the tested strains in both 
planktonic and biofilm culture [29-32]. Unfortunately, PHMB in many trials was shown to need more time in 
comparison to octenidine to reach the desired level of efficacy (PHMB: 15-30 min.; OCT: 30 s to 1 min.) [33]. 
PHMB has anti-biofilm activity, therefore, it can be an interesting option in the treatment of biofilms on 
artificial surfaces [34]. 
In comparsion of activity of 0.2% PHMB, 2.5% sodium hypochlorite and 0.2% chlorhexidine against 
Enterococcus faecalis, Staphylococcus epidermidis and Candida albicans was shown that PHMB and NaOCl 
showed almost the same effectiveness, while CHX was less effective, especially for E. faecalis [35]. 
Polyhexanide has a bactericidal effect also on methicillin-resistant Staphylococcus aureus. The research 
showed that PHMB is a active with a minimum MIC of 1 µg/mL [29]. 
Prolonged in vitro exposure to low levels of polyhexanides may cause reduced sensitivity of MRSA 
strains to polyhexanide without coexisting cross-resistance to chlorhexidine. However, reduced susceptibility 
of polyhexanides may be accompanied by changes in susceptibility to other antibiotics such as vancomycin, 
teicoplanin and daptomycin. Moreover, it were identified mprF mutations in all MRSA strains showing 
resistance to polyhexanide [17].  
In vitro studies conducted on Leishmania sp. confirmed the killing activity of polyhexanide on 
promastigots at sub-micromol levels in a dose-dependent manner. The antiseptic proved to be more potent 
than current standard anti-inflammatory drugs used in clinics. In addition, it directly kills parasites through a 
dual mechanism involving both penetration of parasitic membranes and selective condensation and disruption 
of parasitic chromosomes [36]. Furthermore, other in vitro study has proven the efficacy of 0.02% PHMB 
against Acanthamoeba cyst in patients with positive Acanthamoeba keratosis [37].  
Polyhexanide also exhibits time- and concentration-dependent antifungal activity. The research 
revealed that polyhexanide had the strongest flow against isolates of Fusarium and Exophiala, but showed 
minimal activity against isolates of Aspergillus flavus and A. terreus. It is therefore used as an antiseptic in 
contact lens solutions to prevent the development of fungi leading to eye infection [38]. 
7. CONCLUSION 
The increase in resistance of bacteria to antibiotics complicates the treatment of infections. Antiseptics 
provide low bacterial tolerance and have a broad spectrum of antibacterial effect. PHMB is a substance with 
good antimicrobial activity and safety. 
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